GRAL Competitors & Alternatives

Compare GRAIL, LLC with similar stocks in the same industry

Diagnostics & Research

GRAL

Main Stock
$105.60
-8.88%
Tradestie Score
55
Market Cap
$2.24B
Revenue Growth
3.7%
Analyst Upside
+32.0%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 7/10 Genomics Precision Med Genomic Sequencing
Competitive Moat: None
Core Technology Stack: cfDNA methylation sequencing, machine learning cancer classifiers
Major Customers 4
health systems physicians self-insured employers biopharma partners
Critical Suppliers 3
Illumina sequencing reagents providers lab automation equipment
Direct Ecosystem Rivals 3

Top Competitors

37 stocks in Diagnostics & Research
Company Price Market Cap P/E Score Action
RVMD Revolution Medicines, Inc. Common Stock
$166.87
-3.15%
$8.57B - 44 Compare
CRL Charles River Laboratories International, Inc.
$335.52
-0.72%
$8.39B 367.4 45 Compare
GH Guardant Health, Inc. Common Stock
$144.03
-5.06%
$7.81B - 48 Compare
RDNT RadNet, Inc. Common Stock
$76.89
+0.62%
$6.00B - 45 Compare
BLLN BLLN
$96.31
-8.41%
$5.02B 114.3 35 Compare
SHC Sotera Health Company Common Stock
$16.25
-2.17%
$4.60B 27.7 60 Compare
WGS GeneDx Holdings Corp. Class A Common Stock
$51.02
-2.58%
$3.26B - 50 Compare
VCYT Veracyte, Inc.
$24.01
-1.32%
$2.85B 15.8 47 Compare
ADPT Adaptive Biotechnologies Corporation Common Stock
$27.87
-4.03%
$2.22B - 45 Compare
TWST Twist Bioscience Corporation Common Stock
$105.04
-5.88%
$1.77B - 52 Compare

Data updated: Nov 16, 2026 | Industry: Diagnostics & Research (SIC 8071)

37 stocks in this industry